Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib vs Teriflunomide in Relapsing MS (GEMINI 2)
NCT04410991Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of tolebrutinib in multiple sclerosis (MS), sponsored by Sanofi. Started Jun 2020; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04410991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410991.